Endra Life Sciences initiates review of strategic alternatives

ENDRA Life Sciences (NDRA)’ Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or sale or merger of the Company.ENDRA has engaged Lucid Capital Management as its financial advisor and K&L Gates as its legal counsel in connection with this process. “The Board and management are committed to identifying and evaluating opportunities that may maximize the shareholder value while building on the progress we’ve made advancing ENDRA’s strategic priorities,” said Alexander Tokman, CEO. “We believe this process will help us assess a range of options available to the Company and determine the most appropriate path forward for ENDRA and its shareholders.